The Inceptiv data give Medtronic more evidence as it tries to increase sales of a product that drove double-digit growth at ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...

A long-term study of patients treated with one of Medtronic’s spinal cord stimulation devices found that 80% continued to use their devices after five years to manage their pain. Abbott’s Proclaim XR ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

Bolt Acquisition Deal Drives BSX Stock Close to 52-Week High Boston Scientific stock is currently trading close to its 52-week high. In the past four trading sessions, the stock has consistently ...

These are tech expert Marc Salzman's top CES picks for USA TODAY after his hands-on with future gadgets and gear in Las Vegas ...

In a new study, scientists at the Leibniz Institute for Neurobiology (LIN) and University Hospital Magdeburg demonstrated ...

Medtronic (NYSE: MDT) today announced 12-month data demonstrating the benefits of its Inceptiv closed-loop spinal cord stimulator (CL-SCS).

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

It is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit www.nalumed.com. Indications for Use Spinal Cord Stimulation — The ...